Nonimmunosuppressive effects of mammalian target of rapamycin inhibitors

Transplantation Reviews

Volumn 22, Issue 1, 2008, Pages 73-81

  Cruzado, Josep M ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AZATHIOPRINE; CALCINEURIN INHIBITOR; CYCLOSPORIN; EVEROLIMUS; HAMARTIN; IMMUNOSUPPRESSIVE AGENT; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PLACEBO; PREDNISONE; RAPAMYCIN; TACROLIMUS; TEMSIROLIMUS; TUBERIN;

ALLERGIC ENCEPHALOMYELITIS; ALZHEIMER DISEASE; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOIMMUNE DISEASE; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CELL AGING; CELL GROWTH; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; DIABETIC NEPHROPATHY; DRUG ELUTING STENT; DRUG MECHANISM; GENE MUTATION; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; HYPERLIPIDEMIA; HYPERTROPHIC CARDIOMYOPATHY; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; KAPOSI SARCOMA; KIDNEY CARCINOMA; KIDNEY DISEASE; KIDNEY POLYCYSTIC DISEASE; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; LUPUS VULGARIS; MALIGNANT NEOPLASTIC DISEASE; METABOLIC SYNDROME X; MULTIPLE SCLEROSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OSTEOPOROSIS; PANCREAS ISLET TRANSPLANTATION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; PROTEINURIA; PSORIASIS; RECURRENT CANCER; RESTENOSIS; RETINA MACULA AGE RELATED DEGENERATION; RHEUMATOID ARTHRITIS; SMOOTH MUSCLE FIBER; TUMOR SUPPRESSOR GENE; VASCULAR DISEASE;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; OBESITY; ORGAN TRANSPLANTATION; PROTEIN KINASES; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 36248931517     PISSN: 0955470X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trre.2007.09.003     Document Type: Article

References (83)

1. Tsang C.K., Qi H., Liu L.F., and Zheng X.F.S. Targeting mammalian target of rapamycin (mTOR) for health and diseases. Drug Discov Today 12 (2007) 112-124
2. Nankivell B.J., Borrows R.J., Fung C.L., O'Connell P.J., Allen R.D., and Chapman J.R. The natural history of chronic allograft nephropathy. N Engl J Med 349 (2003) 2326-2333
3. Ojo A.O., Held P.J., Port F.K., et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 349 (2003) 931-940
4. Kahan B.D. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group. Lancet 356 (2000) 194-202
5. Kahan B.D., Julian B.A., Pescovitz M.D., Vanrenterghem Y., and Neylan J. Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in Caucasian recipients of mismatched primary renal allografts: a phase II trial. Rapamune Study Group. Transplantation 68 (1999) 1526-1532
6. Neumayer H.H., Paradis K., Korn A., et al. Entry-into-human study with the novel immunosuppressant SDZ RAD in stable renal transplant recipients. Br J Clin Pharmacol 48 (1999) 694-703
7. Kahan B.D., Kaplan B., Lorber M.I., et al. RAD in de novo renal transplantation: comparison of three doses on the incidence and severity of acute rejection. Transplantation 71 (2001) 1400-1406
8. Meier-Kriesche H.U., and Hricik D.E. Are we ready to give up on calcineurin inhibitors?. Am J Transplant 6 (2006) 445-446
9. Guerra G., Srinivas T.R., and Meier-Kriesche H.U. Calcineurin inhibitor-free immunosuppression in kidney transplantation. Transpl Int 20 (2007) 813-827
10. Grinyo J.M., and Cruzado J.M. Mycophenolate mofetil and sirolimus combination in renal transplantation. Am J Transplant 6 (2006) 1991-1999
11. Pearl J.P., Parris J., Hale D.A., et al. Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am J Transplant 5 (2005) 465-474
12. Noris M., Casiraghi F., Todeschini M., et al. Regulatory T cells and T cell depletion: role of immunosuppressive drugs. J Am Soc Nephrol 18 (2007) 1007-1018
13. Bestard O., Cruzado J.M., Mestre M., et al. Achieving donor-specific hyporesponsiveness is associated with FOXP3+ regulatory T cell recruitment in human renal allograft infiltrates. J Immunol 179 (2007) 490-499
14. Schmelzle T., and Hall M.N. TOR, a central controller of cell growth. Cell 103 (2000) 253-262
15. Dann S.G., Selvaraj A., and Thomas G. mTOR Complex 1-S6K1 signaling: at the crossroads of obesity, diabetes and cancer. Trends Mol Med 13 (2007) 252-259
16. Um S.H., D'Alessio D., and Thomas G. Nutrient overload, insulin resistance, and ribosomal protein S6 kinase 1, S6K1. Cell Metabolism 3 (2006) 393-402
17. Murakami M., et al. mTOR is essential for growth and proliferation in early mouse embryos and embryonic stem cells. Mol Cell Biol 24 (2004) 6710-6718
18. Gangloff Y.G., et al. Disruption of the mouse mTOR gene leads to early postimplantation lethality and prohibits embryonic stem cell development. Mol Cell Biol 24 (2004) 9508-9516
19. Patel A., Fondrk M.K., Kaftanoglu O., et al. The making of a queen: TOR pathway is a key player in diphenic caste development. PLoS ONE 2 (2007) e509 10.1371/journal.pone.0000509
20. Rui L. A link between protein translation and body weight. J Clin Invest 117 (2007) 310-313
21. Poon M., Badimón J.J., and Fuster V. Overcoming restenosis with sirolimus: from alphabet soup to clinical reality. Lancet 359 (2002) 619-622
22. Marx S.O., Jayaraman T., Go L.O., and Marks A.R. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res 76 (1995) 412-417
23. Poon M., Marx S.O., Gallo R., Badimón J.J., Taubman M.B., and Marks A.R. Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest 98 (1996) 2277-2283
24. Gallo R., Padurean A., Jayaraman T., et al. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation 99 (1999) 2164-2170
25. Poston R.S., Billingham M., Hoyt G., et al. Rapamycin reverses chronic graft vascular disease in a novel cardiac allograft model. Circulation 100 (1999) 67-74
26. Elloso M.M., Azrolan N., Sehgal S.N., et al. Protective effect of the immunosuppressant sirolimus against aortic atherosclerosis in apo E-deficient mice. Am J Transplant 3 (2003) 562-569
27. Hausleiter J., Kastrati A., Mehilli J., et al. OSIRIS Investigators. Randomized, double-blind, placebo-controlled trial of oral sirolimus for restenosis prevention in patients with in-stent restenosis: the Oral Sirolimus to Inhibit Recurrent In-stent Stenosis (OSIRIS) trial. Circulation 110 (2004) 790-795
28. Spaulding C., Daemen J., Boersma E., Cutlip D.E., and Serruys P.W. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Eng J Med 356 (2007) 989-997
29. Eisen H.J., Tuzcu E.M., Dorent R., et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 349 (2003) 847-858
30. Keogh A., Richardson M., Ruygrok P., et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial. Circulation 110 (2004) 2694-2700
31. Castro C., Campistol J.M., Sancho D., Sanchez-Madrid F., Casals E., and Andres V. Rapamycin attenuates atherosclerosis induced by dietary cholesterol in apolipoprotein-deficient mice through a p27 Kip1-independent pathway. Atherosclerosis 172 (2004) 31-38
32. Shiojima I., Sato K., Izumiya Y., et al. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invest 115 (2005) 2108-2118
33. Shioi T., McMullen J.R., Tarnavski O., et al. Rapamycin attenuates load-induced cardiac hypertrophy in mice. Circulation 107 (2003) 1664-1670
34. McMullen J.R., Sherwood M.C., Tarnavski O., et al. Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload. Circulation 109 (2004) 3050-3055
35. Turka-Kmiec A., Jankowska I., Pawlowska J., et al. Reversal of tacrolimus-related hypertrophic cardiomyopathy after conversion to rapamycin in a pediatric liver transplant recipient. Pediatr Transplant 11 (2007) 319-323
36. Jarzembowski T.M., John E., Panaro F., et al. Reversal of tacrolimus-related hypertrophic obstructive cardiomyopathy 5 years after kidney transplant in a 6-year-old recipient. Pediatr Transplant 9 (2005) 117-121
37. Shapiro A.M., Lakey J.R., Ryan E.A., et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Eng J Med 343 (2000) 230-238
38. Bussiere C.T., Lakey J.R., Shapiro A.M., and Korbutt G.S. The impact of the mTOR inhibitor sirolimus on the proliferation and function of pancreatic islet and ductal cells. Diabetologia 49 (2006) 2341-2349
39. Pende M., Kozma S.C., Jaquet M., et al. Hypoinsulinemia, glucose intolerance and diminished beta-cell size in S6K1-deficient mice. Nature 408 (2000) 994-997
40. Neel J.V. The "thrifty genotype" in 1998. Nutr Rev 57 (1999) S2-S9
41. Cota D., Proulx K., Blake K., et al. Hypothalamic mTOR signaling regulates food intake. Science 312 (2006) 927-930
42. Kahn B., and Myers M.G. MTOR tells the brain that the body is hungry. Nat Med 12 (2006) 615-617
43. Le Bacquer O., Petroulakis E., Paglialunga S., et al. Elevated sensitivity to diet-induced obesity and insulin resistance in mice lacking 4E-BP1 and 4E-BP2. J Clin Invest 117 (2007) 387-396
44. Teutonico A., Schena P., and Di Paolo S. Glucose metabolism in renal transplant recipients: effect of calcineurin inhibitor withdrawal and conversion to sirolimus. J Am Soc Nephrol 16 (2005) 3128-3135
45. Krebs M., Brunmair B., Brehm A., et al. The mTOR-pathway regulates nutrient sensitive glucose uptake in man. Diabetes 56 (2007) 1600-1607
46. Yeh W.C., Bierer B.E., and McKnight S.L. Rapamycin inhibits clonal expansion and adipogenic differentiation of 3T3-L1 cells. Prc Natl Acad Sci 92 (1995) 11086-11090
47. Rosen E.D., Hsu C.H., Wang X., et al. C/EBPα induces adipogenesis through PPARγ: a unified pathway. Genes Dev 16 (2002) 22-26
48. Sipula I.J., Brown N.F., and Perdomo G. Rapamycin-mediated inhibition of mammalian target of rapamycin in skeletal muscle cells reduces glucose utilization and increases fatty acid oxidation. Met Clin Exp 55 (2006) 1637-1644
49. Kim J.E., and Chen J. Regulation of peroxisome proliferator-activated receptor-γ activity by mammalian target of rapamycin and amino acids in adipogenesis. Diabetes 53 (2004) 2748-2756
50. Chapman J.R., and Webster A.C. Cancer after renal transplantation: the next challenge. Am J Transplant 4 (2004) 841-842
51. Buell J.F., Gross T.G., and Woodle E.S. Malignancy after transplantation. Transplantation 80 (2005) S254-S264
52. Chapman J.R., and Campistol J.M. Malignancy in renal transplantation: opportunities with proliferation signal inhibitors. Nephrol Dial Transplant 22 (2007) i1-i3
53. Guba M., Graeb C., Jauch K.W., and Geissler E.K. Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation. Transplantation 77 (2004) 1777-1782
54. Wimmer C.D., Rentsch M., Crispin A., et al. The janus face of immunosuppression-de novo malignancy after renal transplantation: the experience of the Transplantation Center Munich. Kidney Int 71 (2007) 1271-1278
55. Gutierrez-Dalmau A., and Campistol J.M. The role of proliferation signal inhibitors in post-transplant malignancies. Nephrol Dial Transplant 22 (2007) i11-i16
56. Hudes G., Carducci M., Tomczak P., et al. Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356 (2007) 2271-2281
57. Kauffman H.M., Cherikh W.s., Cheng Y., Hanto D.W., and Kahan B.D. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 80 (2005) 883-889
58. Campistol J.M., Eris J., Oberbauer R., et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 17 (2006) 581-589
59. Stallone G., Schena A., Infante B., et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 352 (2005) 1317-1323
60. Sieghart W., Fuereder T., Schmid K., et al. Mammalian target o rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation. Transplantation 83 (2007) 425-432
61. van den Akker J.M., Wetzels J.F., and Hoitsma A.J. Proteinuria following conversion from azathioprine to sirolimus in renal transplant recipients. Kidney Int 70 (2006) 1355-1357
62. Ruiz J.C., Campistol J.M., Sanchez-Fructuoso A., et al. Increase of proteinuria after conversion from calcineurin inhibitor to sirolimus-based treatment in kidney transplant patients with chronic allograft dysfunction. Nephrol Dial Transplant 21 (2006) 3252-3257
63. English J., Evan A., Houghton D.C., and Bennett W.M. Cyclosporine-induced acute renal dysfunction in the rat. Evidence of arteriolar vasoconstriction with preservation of tubular function. Transplantation 44 (1987) 135-141
64. Kasinath B.S., Mariappan M.M., Sataranatarajan K., Lee M.J., and Feliers D. mRNA translation: unexplored territory in renal science. J Am Soc Nephrol 17 (2006) 3281-3292
65. Brenner B.M. Nephron adaptation to renal injury or ablation. Am J Physiol 249 (1985) F324-F337
66. Cruzado J.M., Torras J., Riera M., et al. Influence of nephron mass in development of chronic renal failure after prolonged warm renal ischemia. Am J Physiol Renal Physiol 279 (2000) F259-F269
67. Chen J.K., Chen J., Neilson E.G., and Harris R.C. Role of mammalian target of rapamycin signaling in compensatory renal hypertrophy. J Am Soc Nephrol 16 (2005) 1384-1391
68. Diekmann F., Rovira J., Carreras J., et al. Mammalian target of rapamycin inhibition halts the progression of proteinuria in a rat model of reduced renal mass. J Am Soc Nephrol 18 (2007) 2653-2660
69. Bonegio R.G., Fuhro R., Wang Z., et al. Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy. J Am Soc Nephrol 16 (2005) 2063-2072
70. Fervenza F.C., Fitzpatrick P.M., Mertz J., et al. Mayo Nephrology Collaborative Committee. Acute rapamycin nephrotoxicity in native kidneys of patients with chronic glomerulopathies. Nephrol Dial Transplant 19 (2004) 1288-1292
71. Tumlin J.A., Miller D., Near M., Selvaraj S., Hennigar R., and Guasch A. A prospective, open-label trial of sirolimus in the treatment of focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 1 (2006) 109-116
72. Lock H.R., Sacks S.H., and Robson M.G. Rapamycin at subimmunosuppressive levels inhibits mesangial cell proliferation and extracellular matrix production. Am J Physiol Renal Physiol 292 (2007) F76-F81
73. Mason R.M., and Wahab N.A. Extracellular matrix metabolism in diabetic nephropathy. J Am Soc Nephrol 14 (2003) 1358-1373
74. Nagai K., Matsubara T., Mima A., et al. Gas6 induces Akt/mTOR-mediated mesangial hypertrophy in diabetic nephropathy. Kidney Int 68 (2005) 552-561
75. Lloberas N., Cruzado J.M., Franquesa M., et al. Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats. J Am Soc Nephrol 17 (2006) 1395-1404
76. Tao Y., Kim J., Schrier R.W., and Edelstein C.L. Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. J Am Soc Nephrol 16 (2005) 46-51
77. Chapman A.B. Autosomal dominant polycystic kidney disease: time for a change?. J Am Soc Nephrol 18 (2007) 1399-1407
78. Alperovich G., Rama I., Lloberas N., et al. New immunosuppresor strategies in the treatment of murine lupus nephritis. Lupus 16 (2007) 18-24
79. Wienecke R., Fackler I., Linsenmaier U., Mayer K., Licht T., and Kretzler M. Antitumoral activity of rapamycin in renal angiomyolipoma associated with tuberous sclerosis complex. Am J Kidney Dis 48 (2006) E27-E29
80. Herry I., Neukirch C., Debray M.P., Mignon F., and Crestani B. Dramatic effect of sirolimus on renal angiomyolipomas in a patient with tuberous sclerosis complex. Eur J Int Med 18 (2007) 76-77
81. Franz D.N., Leonard J., Tudor C., Chuck G., Care M., Sethuraman G., et al. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol 59 (2006) 490-498
82. Zhu J., Wu J., Frizell E., et al. Rapamycin inhibits hepatic stellate cell proliferation in vitro and limits fibrogenesis in an in vivo model of liver fibrosis. Gastroenterology 117 (1999) 1198-1204
83. Blagosklonny M.V. Aging and immortality. Quasi-programmed senescence and its pharmacologic inhibition. Cell Cycle 5 (2006) 2087-2102